{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:01:57Z","timestamp":1791932517869,"version":"4.3.4"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejim.2026.107036","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:31:42Z","timestamp":1782300702000},"page":"107036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Neutrophil-to-lymphocyte ratio: A disease severity biomarker in stable chronic obstructive pulmonary disease?"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3782-5021","authenticated-orcid":false,"given":"Marco","family":"Vanetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2298-1623","authenticated-orcid":false,"given":"Dina","family":"Visca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ardesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8443-5316","authenticated-orcid":false,"given":"Martina","family":"Zappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pessano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Pignatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-1689","authenticated-orcid":false,"given":"Leonardo M","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-9903","authenticated-orcid":false,"given":"Antonio","family":"Spanevello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2026.107036_bib0001","author":"Global Initiative for Chronic Obstructive Lung Disease"},{"issue":"12","key":"10.1016\/j.ejim.2026.107036_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46598","article-title":"Global burden of chronic obstructive pulmonary disease through 2050","volume":"6","author":"Boers","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.ejim.2026.107036_bib0003","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/resp.14041","article-title":"Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact","volume":"26","author":"MacLeod","year":"2021","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.ejim.2026.107036_bib0004","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12931-024-03033-4","article-title":"Prognostic risk prediction model for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD): a systematic review and meta-analysis","volume":"25","author":"Xu","year":"2024","journal-title":"Respir Res"},{"key":"10.1016\/j.ejim.2026.107036_bib0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1741-7015-11-181","article-title":"Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease","volume":"11","author":"Wedzicha","year":"2013","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.ejim.2026.107036_bib0006","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S2213-2600(23)00261-8","article-title":"COPD and multimorbidity: recognising and addressing a syndemic occurrence","volume":"11","author":"Fabbri","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.ejim.2026.107036_bib0007","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s12325-024-02855-4","article-title":"Implications of cardiopulmonary risk for the management of COPD: a narrative review","volume":"41","author":"Singh","year":"2024","journal-title":"Adv Ther"},{"issue":"4\u20135","key":"10.1016\/j.ejim.2026.107036_bib0008","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14779072.2024.2333786","article-title":"Cardiovascular disease and risk in COPD: a state of the art review","volume":"22","author":"Polman","year":"2024","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"1","key":"10.1016\/j.ejim.2026.107036_bib0009","article-title":"Rate of severe exacerbations, healthcare resource utilisation and clinical outcomes in patients with COPD in low-income and middle-income countries: results from the EXACOS International Study","volume":"11","author":"Athanazio","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.ejim.2026.107036_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221113647","article-title":"Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"M\u00fcllerov\u00e1","year":"2022","journal-title":"Ther Adv Respir Dis"},{"issue":"18","key":"10.1016\/j.ejim.2026.107036_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024350","article-title":"Time-dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial","volume":"11","author":"Dransfield","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.ejim.2026.107036_bib0012","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1164\/rccm.202307-1122OC","article-title":"Temporal risk of nonfatal cardiovascular events after chronic obstructive pulmonary disease exacerbation: a population-based study","volume":"209","author":"Graul","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.ejim.2026.107036_bib0013","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1164\/rccm.202401-0040ED","article-title":"Risk and prevention of cardiovacular events after exacerbations of respiratory symptoms in patients with COPD","volume":"209","author":"Beghe","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"34","key":"10.1016\/j.ejim.2026.107036_bib0014","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.107036_bib0015","doi-asserted-by":"crossref","first-page":"6603","DOI":"10.2147\/JIR.S478568","article-title":"Inflammatory and immune mechanisms in COPD: current status and therapeutic prospects","volume":"17","author":"Qi","year":"2024","journal-title":"J Inflamm Res"},{"issue":"20","key":"10.1016\/j.ejim.2026.107036_bib0016","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1042\/CS20255452","article-title":"COPD: the role of neutrophils in inflammation, pathophysiology, and as drug targets","volume":"139","author":"Fricker","year":"2025","journal-title":"Clin Sci (Lond)"},{"issue":"25","key":"10.1016\/j.ejim.2026.107036_bib0017","first-page":"2484","article-title":"Update on the pathogenesis of COPD. reply","volume":"381","author":"Agust\u00ed","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.107036_bib0018","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41598-020-79431-7","article-title":"Neutrophil-to-lymphocyte ratio and mortality in the United States general population","volume":"11","author":"Song","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejim.2026.107036_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2023.104598","article-title":"Neutrophil-to-lymphocyte ratio an inflammatory biomarker, and prognostic marker in heart failure, cardiovascular disease and chronic inflammatory diseases: new insights for a potential predictor of anti-cytokine therapy responsiveness","volume":"150","author":"Garc\u00eda-Escobar","year":"2023","journal-title":"Microvasc Res"},{"issue":"7","key":"10.1016\/j.ejim.2026.107036_bib0020","first-page":"474","article-title":"Neutrophil-to-lymphocyte ratio, past, present and future perspectives","volume":"122","author":"Zahorec","year":"2021","journal-title":"Bratisl Lek Listy"},{"issue":"9","key":"10.1016\/j.ejim.2026.107036_bib0021","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ejim.2026.107036_bib0022","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijcard.2013.12.019","article-title":"Neutrophil lymphocyte ratio significantly improves the Framingham risk score in prediction of coronary heart disease mortality: insights from the National Health and Nutrition Examination Survey-III","volume":"171","author":"Shah","year":"2014","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2026.107036_bib0023","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejim.2026.107036_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105949","article-title":"Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with systemic lupus erythematosus and their correlation with activity: a meta-analysis","volume":"76","author":"Ma","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ejim.2026.107036_bib0025","article-title":"Could a simple biomarker as neutrophil-to-lymphocyte ratio reflect complex processes orchestrated by neutrophils?","volume":"6","author":"Kourilovitch","year":"2023","journal-title":"J Transl Autoimmun"},{"issue":"166","key":"10.1016\/j.ejim.2026.107036_bib0026","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0095-2022","article-title":"Clinical significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute exacerbations of COPD: present and future","volume":"31","author":"Zinellu","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.ejim.2026.107036_bib0027","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"25","key":"10.1016\/j.ejim.2026.107036_bib0028","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.ejim.2026.107036_bib0029","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.ejim.2026.107036_bib0030","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","article-title":"Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm","volume":"43","author":"Hageman","year":"2022","journal-title":"Eur Heart J"},{"issue":"42","key":"10.1016\/j.ejim.2026.107036_bib0031","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2026.107036_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101459","article-title":"Estimating the Risk of Cardiovascular Events in U.S. Veterans Using the SMART Risk Score","volume":"4","author":"Banerjee","year":"2025","journal-title":"JACC Adv"},{"issue":"5","key":"10.1016\/j.ejim.2026.107036_bib0033","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1183\/09031936.00128008","article-title":"Systemic manifestations and comorbidities of COPD","volume":"33","author":"Barnes","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2026.107036_bib0034","article-title":"Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities","author":"Agusti","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.ejim.2026.107036_bib0035","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1513\/AnnalsATS.202510-1079ED","article-title":"Neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease: a simple marker with complex implications","volume":"22","author":"LeMaster","year":"2025","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.ejim.2026.107036_bib0036","first-page":"187","article-title":"The neutrophil-to-lymphocyte ratio as a predictor of acute exacerbations among patients with COPD in uganda","volume":"11","author":"Alupo","year":"2024","journal-title":"Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.ejim.2026.107036_bib0037","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/COPD.S290422","article-title":"Neutrophil-to-lymphocyte ratio predicts clinical outcome of severe acute exacerbation of COPD in frequent exacerbators","volume":"16","author":"Lu","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"8","key":"10.1016\/j.ejim.2026.107036_bib0038","doi-asserted-by":"crossref","DOI":"10.1111\/eci.12984","article-title":"The neutrophil-to-lymphocyte ratio as a marker of chronic obstructive pulmonary disease and its exacerbations: a systematic review and meta-analysis","volume":"48","author":"Paliogiannis","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejim.2026.107036_bib0039","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.2147\/COPD.S178068","article-title":"Defining the role of neutrophil-to-lymphocyte ratio in COPD: a systematic literature review","volume":"13","author":"Pascual-Gonz\u00e1lez","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"10.1016\/j.ejim.2026.107036_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156511","article-title":"Association of the neutrophil-to-lymphocyte ratio with lung function and exacerbations in patients with chronic obstructive pulmonary disease","volume":"11","author":"Lee","year":"2016","journal-title":"PLoS One"},{"issue":"28","key":"10.1016\/j.ejim.2026.107036_bib0041","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016371","article-title":"The prognostic values of neutrophil to lymphocyte ratio for outcomes in chronic obstructive pulmonary disease","volume":"98","author":"Ye","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.ejim.2026.107036_bib0042","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2147\/COPD.S452444","article-title":"Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Monocyte-to-Lymphocyte Ratio (MLR) as biomarkers in diagnosis evaluation of acute exacerbation of chronic obstructive pulmonary disease: a retrospective, observational study","volume":"19","author":"Cai","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"12","key":"10.1016\/j.ejim.2026.107036_bib0043","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Investigators EoCLtIPSEE. Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejim.2026.107036_bib0044","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ejim.2026.107036_bib0045","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1164\/rccm.202406-1254CI","article-title":"Is disease stability an attainable chronic obstructive pulmonary disease treatment goal?","volume":"211","author":"Singh","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.ejim.2026.107036_bib0046","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1513\/AnnalsATS.202412-1265OC","article-title":"Neutrophil-to-lymphocyte ratio as a biomarker in clinically stable chronic obstructive pulmonary disease: SPIROMICS cohort","volume":"22","author":"Hoesterey","year":"2025","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"10.1016\/j.ejim.2026.107036_bib0047","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiaf133","article-title":"Low-density granulocytes in the pathogenesis of inflammatory disease","volume":"117","author":"Nutley","year":"2025","journal-title":"J Leukoc Biol"},{"issue":"2","key":"10.1016\/j.ejim.2026.107036_bib0048","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jaci.2025.04.011","article-title":"Innate immune reprogramming in circulating neutrophils of COPD patients","volume":"156","author":"Mariotti","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.ejim.2026.107036_bib0049","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/thx.2006.072348","article-title":"Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee","volume":"62","author":"McGarvey","year":"2007","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.ejim.2026.107036_bib0050","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/thorax-2023-220615","article-title":"QRISK3 underestimates the risk of cardiovascular events in patients with COPD","volume":"79","author":"Amegadzie","year":"2024","journal-title":"Thorax"},{"issue":"15","key":"10.1016\/j.ejim.2026.107036_bib0051","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/eurjpc\/zwaf119","article-title":"Identification and management of cardiopulmonary risk in patients with chronic obstructive pulmonary disease: a multidisciplinary consensus and modified Delphi study","volume":"32","author":"Gale","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2026.107036_bib0052","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.amjcard.2018.10.036","article-title":"Relation of neutrophil to lymphocyte ratio to risk of incident atrial fibrillation","volume":"123","author":"Berkovitch","year":"2019","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2026.107036_bib0053","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.arcmed.2015.03.011","article-title":"Usefulness of neutrophil\/lymphocyte ratio as a predictor of atrial fibrillation: a meta-analysis","volume":"46","author":"Shao","year":"2015","journal-title":"Arch Med Res"},{"issue":"18","key":"10.1016\/j.ejim.2026.107036_bib0054","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/eurheartj\/ehi291","article-title":"Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease","volume":"26","author":"Rutten","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.107036_bib0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.902955","article-title":"The clinical relevance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in chronic obstructive pulmonary disease with lung cancer","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol"},{"issue":"13","key":"10.1016\/j.ejim.2026.107036_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19138077","article-title":"Higher neutrophil-to-lymphocyte ratio was associated with increased risk of chronic kidney disease in overweight\/obese but not normal-weight individuals","volume":"19","author":"Lin","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.ejim.2026.107036_bib0057","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cca.2018.07.025","article-title":"Age and sex differences in the relationship between neutrophil-to-lymphocyte ratio and chronic kidney disease among an adult population in Taiwan","volume":"486","author":"Kuo","year":"2018","journal-title":"Clin Chim Acta"},{"issue":"24","key":"10.1016\/j.ejim.2026.107036_bib0058","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038512","article-title":"Relationship between neutrophil lymphocyte ratio and red blood cell distribution width and respiratory failure in COPD patients","volume":"103","author":"Li","year":"2024","journal-title":"Medicine"},{"issue":"7","key":"10.1016\/j.ejim.2026.107036_bib0059","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.10350","article-title":"Association of neutrophil to lymphocyte ratio with pulmonary function in a 30-year longitudinal study of US veterans","volume":"3","author":"Gao","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.ejim.2026.107036_bib0060","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1513\/AnnalsATS.202009-1197OC","article-title":"Mortality and healthcare use of patients with compensated hypercapnia","volume":"18","author":"Wilson","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"10.1016\/j.ejim.2026.107036_bib0061","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008909","article-title":"Is hypercapnia associated with poor prognosis in chronic obstructive pulmonary disease? A long-term follow-up cohort study","volume":"5","author":"Yang","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejim.2026.107036_bib0062","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2147\/COPD.S242809","volume":"15","author":"Bikov","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ejim.2026.107036_bib0063","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251335800","article-title":"Eosinophils in chronic obstructive pulmonary disease","volume":"19","author":"Vanetti","year":"2025","journal-title":"Ther Adv Respir Dis"},{"issue":"5","key":"10.1016\/j.ejim.2026.107036_bib0064","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","article-title":"Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial","volume":"29","author":"Siva","year":"2007","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ejim.2026.107036_bib0065","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.107036_bib0066","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejim.2026.107036_bib0067","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Investigators I. Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejim.2026.107036_bib0068","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.37765\/ajmc.2020.42837","article-title":"Initiation of triple therapy maintenance treatment among patients with COPD","volume":"26","author":"Li","year":"2020","journal-title":"Am J Manag Care"},{"issue":"12","key":"10.1016\/j.ejim.2026.107036_bib0069","article-title":"Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease","volume":"12","author":"van Geffen","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ejim.2026.107036_bib0070","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00471-2021","article-title":"Neutrophil-to-lymphocyte ratio, blood eosinophils and COPD exacerbations: a cohort study","volume":"7","author":"Ellingsen","year":"2021","journal-title":"ERJ Open Res"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526003419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526003419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:06:04Z","timestamp":1788260764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526003419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":70,"alternative-id":["S0953620526003419"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107036","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutrophil-to-lymphocyte ratio: A disease severity biomarker in stable chronic obstructive pulmonary disease?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"107036"}}